Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines.

• DOI: 10.3892/ijo.14.6.1097
• Publication Date: 2014-03-10T03:25:11Z
• Authors: B Brenner; E Rakowsky; A Katz; H Gutman; A Sulkes; J Schacter; E Fenig
• Keywords: Immunosuppression; Localized disease

Classical Kaposi's sarcoma (CKS) is a rare indolent proliferative disease which particularly prevalent among Jews of Ashkenazi and Mediterranean origin. To define guidelines for its comprehensive management, we conducted retrospective analysis 123 patients, focusing mainly on treatment modalities. The CKS-related mortality was 4% (5 patients). Of the 39 patients whom observation only primary approach, 15 (38%) remained progression-free 1-83 months (median, 4 months). Twenty-nine 52 (56%) who underwent surgery as approach recurrence-free 1-162 Radiotherapy achieved an objective response in 74 courses (85%), including 50 (58%) complete responses. Symptomatic relief reported 95% patients. Vinblastine (27 series) 73% series, 22% Multivariate time to progression with alone identified immunosuppression significant independent factor that predicted progression. Our study suggests may be sufficient immunocompetent asymptomatic patients; symptomatic resectable lesions are suitable simple excision; more advanced or unresectable require radiotherapy. If extensive other approaches fail, chemotherapy appropriate. Tailoring CKS integrative process, requiring good understanding role each available modality different clinical settings.